Search and analyze individual stocks with comprehensive metrics

Indraprastha Medical Corporation Limited

INDRAMEDCOHealthcare Services

Fundamental Score

...

Indraprastha Medical Corporation Limited Share Price & Market Analysis

Current Market Price (CMP)
457.70
No change data available
Market Cap
4.20K (Cr)
Industry
Healthcare Services

Profitability Metrics

Excellent

Return on Equity

30.04%
Excellent

Return on Capital Employed

39.10%
Excellent

Operating Profit Margin (5Y)

14.46%
Average

Dividend Yield

0.98%

Valuation Metrics

Excellent

Price to Earnings

25.03x

Market Capitalization

4.20K (Cr)

Industry P/E

54.87x

Growth Metrics

Poor

YoY Quarterly Profit Growth

14.94%
Poor

YoY Quarterly Sales Growth

4.94%
Average

Sales Growth (5Y)

10.30%
Excellent

EPS Growth (5Y)

29.45%
Excellent

Profit Growth (5Y)

29.45%

Financial Health

Excellent

Debt to Equity

0.05x
Excellent

Interest Coverage

37.18x
Excellent

Free Cash Flow (5Y)

421.74 (Cr)

Ownership Structure

Good

Promoter Holding

51.00%
Poor

FII Holding

2.73%
Poor

DII Holding

3.56%
Excellent

Pledged Percentage

0.00%
Market-cap Classification
Small-cap
Higher growth potential with higher volatility.
51.00%
Promoter Holding
4.20K (Cr)
Market Cap

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Market Data Analysis & Educational Insights

Educational evaluation of INDRAMEDCO across key market metrics for learning purposes.

Positive Indicators

10 factors identified

Strong Return on Equity (30.04%)

Observation: Efficient use of shareholders' capital generating superior returns.

Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.

Excellent ROCE Performance (39.10%)

Observation: Superior returns on capital employed across business operations.

Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance. This indicates quality business fundamentals.

Attractive Valuation (P/E: 25.03 vs Industry: 54.87)

Observation: Trading at discount to industry peers.

Analysis: P/E below industry average may present value opportunity if fundamentals support the business case.

Excellent EPS Growth (29.45% CAGR)

Observation: Outstanding 5-year earnings per share compound growth.

Analysis: EPS CAGR >15% indicates strong wealth creation potential and effective capital allocation over extended periods.

Strong Profit Growth Track Record (29.45% CAGR)

Observation: Consistent 5-year profit compound annual growth rate.

Analysis: Profit CAGR >15% demonstrates scalable business model and effective operational leverage over time.

Conservative Debt Levels (D/E: 0.05)

Observation: Low leverage provides financial flexibility and reduced risk.

Analysis: Conservative debt structure offers resilience during economic downturns and flexibility for growth investments.

Strong Interest Coverage (37.18x)

Observation: Earnings comfortably cover interest obligations.

Analysis: Interest coverage >5x indicates low financial distress risk and strong debt servicing capability.

Strong Cash Generation (₹421.74 Cr over 5Y)

Observation: Healthy free cash flow generation supports growth and returns.

Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.

Balanced Promoter Holding (51.00%)

Observation: Optimal balance between promoter control and public float.

Analysis: Promoter holding in 50-75% range provides management alignment while ensuring adequate liquidity.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral, reducing forced-selling risk.

Analysis: Absence of share pledging eliminates potential forced-selling pressure during market stress.

Risk Factors

1 factors identified

Limited Institutional Interest (FII+DII: 6.29%)

Observation: Low institutional participation may affect liquidity and visibility.

Analysis: Limited institutional interest may indicate size constraints or visibility issues in the investment community.

📊 Educational Market Overview

Disclaimer: The ratings and scores are generated algorithmically from publicly available market data and are provided for educational and informational purposes only. They do not constitute investment advice, recommendation, or solicitation to buy/sell any securities.

Loading Peer Comparison

Finding companies in the Hospital sector...

Financial Statements

Comprehensive financial data for Indraprastha Medical Corporation Limited

About INDRAMEDCO

Company Details

Symbol:INDRAMEDCO
Industry:Healthcare Services
Sector:Hospital

Market Information

Market Cap:4.20K (Cr)
P/E Ratio:25.03
Beta:N/A

Performance

52W High:N/A
52W Low:N/A
Dividend Yield:0.98%

INDRAMEDCO Stock Details & Analysis

Key Financial Metrics

Return on Equity (ROE)30.04%
Return on Capital Employed39.10%
Operating Profit Margin (5Y)14.46%
Debt to Equity Ratio0.05
Interest Coverage Ratio37.18

Growth & Valuation

Sales Growth (5Y)10.30%
Profit Growth (5Y)29.45%
EPS Growth (5Y)29.45%
YoY Quarterly Profit Growth14.94%
YoY Quarterly Sales Growth4.94%

Frequently Asked Questions

What is the current price of INDRAMEDCO?

INDRAMEDCO is currently trading at ₹457.70 with a gain of 0.00% today. The current market price (CMP) represents the last traded price of INDRAMEDCO shares on the stock exchange. This price fluctuates throughout trading hours based on supply and demand. You can track real-time price movements, percentage changes, and trading volume in the header section.

What is the P/E ratio of INDRAMEDCO and what does it mean?

INDRAMEDCO has a P/E ratio of 25.03x compared to the industry average of 54.87x. The Price-to-Earnings (P/E) ratio is calculated by dividing the current share price by earnings per share (EPS). This means investors are paying ₹25 for every ₹1 of annual earnings. This is lower than the industry average, which might indicate undervaluation or slower growth expectations.

How is INDRAMEDCO performing according to Bull Run's analysis?

INDRAMEDCO has a Bull Run fundamental score of 65.5/100, which indicates moderate strength with some areas for improvement. This comprehensive rating is based on 15+ financial parameters including profitability (ROE: 30.04%), growth metrics, valuation ratios, and financial health indicators. The score updates quarterly with new financial data and helps you quickly assess overall investment quality.

What sector and industry does INDRAMEDCO belong to?

INDRAMEDCO operates in the Healthcare Services industry. This sector classification helps understand the broader economic trends, regulatory framework, and competitive landscape affecting Indraprastha Medical Corporation Limited. Companies in this industry typically face similar market dynamics, cyclical patterns, and macroeconomic factors. Understanding the industry context is crucial for peer comparison and assessing how sector-specific trends might impact the stock's performance.

What is Return on Equity (ROE) and why is it important for INDRAMEDCO?

INDRAMEDCO has an ROE of 30.04%, which indicates excellent management efficiency and profitable operations. Return on Equity measures how efficiently Indraprastha Medical Corporation Limited generates profits from shareholders' equity. An ROE of 30% means the company generates ₹30 profit for every ₹100 of shareholders' equity. This metric is crucial for assessing management's ability to create value for shareholders.

How is INDRAMEDCO's debt-to-equity ratio and what does it indicate?

INDRAMEDCO has a debt-to-equity ratio of 0.05, which indicates conservative financing with low financial risk. This means the company has ₹5 of debt for every ₹100 of equity. This conservative approach provides financial stability but may limit growth potential.

What is INDRAMEDCO's dividend yield and is it a good dividend stock?

INDRAMEDCO offers a dividend yield of 0.98%, which means you receive ₹0.98 annual dividend for every ₹100 invested. The focus appears to be more on growth rather than dividend income. Dividend yield is calculated as annual dividend per share ÷ current share price × 100. Evaluate dividend consistency over 5+ years and free cash flow coverage for sustainability.

How has INDRAMEDCO grown over the past 5 years?

INDRAMEDCO has achieved 5-year growth rates of: Sales Growth 10.30%, Profit Growth 29.45%, and EPS Growth 29.45%. These growth metrics show the company's ability to expand its business and improve profitability over time. Sales growth indicates market expansion, profit growth shows operational efficiency, and EPS growth directly impacts share price appreciation potential.

What is the promoter holding in INDRAMEDCO and why does it matter?

Promoters hold 51.00% of INDRAMEDCO shares, with 0.00% of promoter shares pledged. This high promoter holding indicates strong management confidence and alignment with shareholders. Low pledging indicates financial stability of promoters. Recent change in promoter holding: 0.00%.

How does INDRAMEDCO compare with its industry peers?

INDRAMEDCO trades at P/E 25.03x vs industry average 54.87x, with ROE of 30.04% and ROCE of 39.10%. The stock appears undervalued relative to peers based on P/E ratio. Peer comparison helps identify whether INDRAMEDCO is outperforming its competitive set in profitability, growth, and valuation metrics.

What is INDRAMEDCO's market capitalization and what category does it fall into?

INDRAMEDCO has a market capitalization of ₹4197 crores, making it a Large-cap stock. Large-cap stocks offer stability and liquidity but typically slower growth. Market cap is calculated as current share price × total outstanding shares, representing the company's total market value.

What are the key financial ratios to consider for INDRAMEDCO?

Key ratios for INDRAMEDCO: ROE 30.04% (Excellent), ROCE 39.10%, P/E 25.03x, Debt-to-Equity 0.05, Interest Coverage 37.18x. These ratios help assess profitability (ROE, ROCE), valuation (P/E), financial health (D/E, Interest Coverage), and overall investment quality. Compare these with industry medians and historical trends for meaningful analysis.

How volatile is INDRAMEDCO stock and what is its beta?

INDRAMEDCO has a beta of N/A, which means it is less volatile than the market and offers defensive characteristics. Beta measures price volatility relative to the Nifty 50. Lower beta stocks provide stability during uncertain market conditions. Consider beta alongside your risk tolerance and portfolio diversification strategy.

What is the 52-week high and low for INDRAMEDCO?

INDRAMEDCO has a 52-week high of ₹N/A and low of ₹N/A. Currently trading at ₹457.70, the stock is within its annual trading range. Trading near highs indicates strong momentum but limited upside potential.

What are the key risks associated with investing in INDRAMEDCO?

Key risks for INDRAMEDCO include: Market volatility (Beta: N/A), financial leverage (Debt-to-Equity: 0.05), and operational challenges. The stock has a Fundamental Score of 65.5/100, indicating moderate risk requiring careful monitoring. Sector-specific risks in Healthcare Services include regulatory changes, economic cycles, and competitive pressures. Consider your risk tolerance, investment horizon, and portfolio diversification before investing. Past performance doesn't guarantee future results.

What is INDRAMEDCO's operating profit margin and how has it trended?

INDRAMEDCO has a 5-year average Operating Profit Margin (OPM) of 14.46%, which is good and shows decent operational efficiency. Operating Profit Margin shows operational efficiency by measuring operating profit as a percentage of revenue. Monitor margin trends to assess management's ability to control costs and improve efficiency. Compare with industry peers to understand relative performance.

How is INDRAMEDCO's quarterly performance in terms of sales and profit growth?

INDRAMEDCO's recent quarterly performance shows YoY Sales Growth of 4.94% and YoY Profit Growth of 14.94%. Growth rates indicate the current business trajectory and market demand. Sales growth shows market demand while profit growth reveals operational efficiency and margin management.

What is the FII and DII holding pattern in INDRAMEDCO?

INDRAMEDCO has FII holding of 2.73% and DII holding of 3.56%, totaling 6.29% institutional ownership. This institutional participation level shows the confidence of professional money managers. Monitor quarterly changes in institutional holdings for investment flow trends and sentiment.